Ethical Implications of Patient Access Restrictions

Jessica Nance, MD, MS, and Emma Ciafaloni, MD, FAAN, discuss ethical dilemmas, exploring how patient subgroup restrictions on orphan drugs can impact access and cost control.

Related Keywords

Kimberlyc Chen ,Emma Ciafaloni ,Ryan Haumschild ,Mary Pak ,Peer Exchange ,Jessica Nance ,Collaboration ,Gene Therapy ,Managed Care ,Patient Access ,Healthcare ,Clinical Data ,Rare Diseases ,Treatment Options ,Ethical Implications ,Cost Effectiveness ,Equity ,Coverage Determinations , ,Clinical Evidence ,Patient Population ,Financial Sustainability ,Subscription Models ,Warranty Programs ,Performance Based Contracts ,Value Based Contracting ,Patient Advocacy ,Research And Development ,Innovative Therapies ,Communication ,Data Sharing ,Equitable Access ,Patient Centered Care ,Provider Collaboration ,Payer Perspectives ,Treatment Affordability ,Health System Strategies ,